undamentalytics Newsletter
Sign in

Zepp Health Corp (ZEPP) stock

Add to watchlist

Add holding +

NYSE: ZEPP NYSE Consumer Electronics Next results ~November 4, 2026

B Fundamentals grade

Zepp Health Corp is a US-listed company in the consumer electronics industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$41

Revenue-to-maturity cash-flow model

Base case. Range ~$32–$53 across our lower- and higher-growth cases (25%–35% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Zepp Health Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds17 adding, 17 cuttingOf 8 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Zepp Health files

Where Zepp Health stands after its latest Filing

Revenue for the twelve months was $259m, up 41.8% on a year earlier, against a decline of 48.3% a quarter earlier. That growth ranks 2 of 11 among the consumer electronics companies we cover. Free-cash-flow margin fell to -10.1% from -4.5% a year earlier. Operating margin narrowed to -11.3% from 1.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 3 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $41.18 a share, against a share price of $2.20.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Zepp Health Corp's trailing-twelve-month revenue grew 41.8% year on year, with a free-cash-flow margin of -10.1%. Where it stands out: change in growth rate of +90.0pp ranks 1 of 11 consumer electronics companies we cover. Where it lags: days sales outstanding of 94 days ranks 10 of 10 consumer electronics companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 41.8% (+90.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 41.8% over the last 12 months, against a median of -17.9% for consumer electronics companies we cover.
  • Growth speeding up. The growth rate is 90.0 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 14.6 points on a year ago.
  • Shrinking share count. Diluted shares fell 1.7% in a year, so each share owns more of the business.

Things to watch

  • Loss-making. Operating margin is -11.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -10.1% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 102% and a beta of 2.2 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 94 days ranks 10 of 10 consumer electronics companies we cover (median 53 days).

Price chart

  • 1 day+1.4%
  • 1 week-12.2%
  • 1 month-41.6%
  • This year-91.7%
  • 1 year-94.5%
  • 5 years-93.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$259M
Operating margin
-11.3%
Net margin
-15.5%
EPS (TTM, diluted)
$-2.52

Growth

Revenue growth
+41.8%
Change in growth rate
+90.0 pts
Share count change
−1.7%

Cash

Free cash flow (TTM)
-$26.2M
FCF margin
-10.1%
Stock pay % of revenue
1.0%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for ZEPP from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Zepp Health Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Zepp Health Corp as an operating company, with every model that fits that kind of business. Cost of equity 11.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.53 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$41 ~$32–$53 Left out: out of range vs price (18.58x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.6 ~$6.7–$24 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.6 ~$1.6–$24 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Zepp Health Corp with Consumer Electronics in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025
Share price$38.03$46.50$45.85$19.54$5.80$5.68$2.60$26.94
Market value$535m$744m$746m$323m$89m$86m$42m$428m
+ Net debt (− = net cash)−$207m−$259m−$339m−$100m$37m$53m$46m$114m
Enterprise value$328m$485m$407m$223m$126m$140m$88m$543m
Multiples
Price / sales 1.0x0.9x0.8x0.3x0.1x0.2x0.2x1.7x
Price / earnings 10.8x9.0x21.3x14.9x————
Price / free cash flow 5.3x13.2x66.0x——2.1x——
EV / EBITDA 6.1x5.5x13.2x9.7x————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current — — $2.0bn +14%
Next — — $2.2bn +7%

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Zepp Health Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.2%
of tradable shares
Days to cover
14.09
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
34%
of shares
Held by insiders
22.2%
of shares
Employees
763
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ZEPP−57%−70%−2%−54%+936%−92%
Industry peers (median)+16%−43%−31%−24%−44%−17%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ZEPP33%17%50%17%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ZEPP−77%−78%−54%−74%−63%−93%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 8, 2018: 97% from February 19, 2021 to August 5, 2024. Getting back needed a 3604% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.20 – $38.90
From 52-week high
−94.3%
vs 50-day average
−42.8%
vs 200-day average
−77.9%
Volatility (1 year)
102%
Beta vs S&P 500
2.20

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Zepp Health Corp in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Zepp Health Corp
$0 $500M $1B FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY17 Q4: $314.9M Revenue (TTM), FY18 Q4: $530.2M Revenue (TTM), FY19 Q4: $834.9M Revenue (TTM), FY20 Q4: $986M Revenue (TTM), FY21 Q4: $980.8M Revenue (TTM), FY22 Q4: $613.6M Revenue (TTM), FY23 Q4: $352.9M Revenue (TTM), FY24 Q4: $182.6M Revenue (TTM), FY25 Q4: $258.9M $258.9M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY17 Q4 $314.9M
FY18 Q4 $530.2M
FY19 Q4 $834.9M
FY20 Q4 $986M
FY21 Q4 $980.8M
FY22 Q4 $613.6M
FY23 Q4 $352.9M
FY24 Q4 $182.6M
FY25 Q4 $258.9M
Revenue growth, TTM YoY Zepp Health Corp
-50% 0% 50% 100% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY18 Q4: 68.4% Revenue growth, TTM YoY, FY19 Q4: 57.5% Revenue growth, TTM YoY, FY20 Q4: 18.1% Revenue growth, TTM YoY, FY21 Q4: -0.5% Revenue growth, TTM YoY, FY22 Q4: -37.4% Revenue growth, TTM YoY, FY23 Q4: -42.5% Revenue growth, TTM YoY, FY24 Q4: -48.3% Revenue growth, TTM YoY, FY25 Q4: 41.8% 41.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 68.4%
FY19 Q4 57.5%
FY20 Q4 18.1%
FY21 Q4 -0.5%
FY22 Q4 -37.4%
FY23 Q4 -42.5%
FY24 Q4 -48.3%
FY25 Q4 41.8%
Operating margin (TTM) Zepp Health Corp
-30% -20% -10% 0% 10% 20% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY17 Q4: 8.9% Operating margin (TTM), FY18 Q4: 10.0% Operating margin (TTM), FY19 Q4: 10.4% Operating margin (TTM), FY20 Q4: 2.7% Operating margin (TTM), FY21 Q4: 1.5% Operating margin (TTM), FY22 Q4: -10.1% Operating margin (TTM), FY23 Q4: -8.6% Operating margin (TTM), FY24 Q4: -25.9% Operating margin (TTM), FY25 Q4: -11.3% -11.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY17 Q4 8.9%
FY18 Q4 10.0%
FY19 Q4 10.4%
FY20 Q4 2.7%
FY21 Q4 1.5%
FY22 Q4 -10.1%
FY23 Q4 -8.6%
FY24 Q4 -25.9%
FY25 Q4 -11.3%
FCF margin (TTM) Zepp Health Corp
-20% -10% 0% 10% 20% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY17 Q4: 10.6% FCF margin (TTM), FY18 Q4: 18.9% FCF margin (TTM), FY19 Q4: 6.8% FCF margin (TTM), FY20 Q4: 1.1% FCF margin (TTM), FY21 Q4: -4.5% FCF margin (TTM), FY22 Q4: -19.3% FCF margin (TTM), FY23 Q4: 11.6% FCF margin (TTM), FY24 Q4: -14.1% FCF margin (TTM), FY25 Q4: -10.1% -10.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY17 Q4 10.6%
FY18 Q4 18.9%
FY19 Q4 6.8%
FY20 Q4 1.1%
FY21 Q4 -4.5%
FY22 Q4 -19.3%
FY23 Q4 11.6%
FY24 Q4 -14.1%
FY25 Q4 -10.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 143 235 315 530 835 986 981 614 353 183 259
Gross profit 18 42 76 137 211 204 205 119 92 70 99
EBITDA −6 2 29 54 88 31 23 −53 −23 −42 −25
Operating income −6 2 28 53 87 27 15 −62 −30 −47 −29
Net income −6 4 26 49 83 35 22 −43 −31 −76 −40
Diluted EPS — — — — $5.12 $2.08 $1.28 −$2.88 −$2.08 −$4.64 −$2.56
Growth (year on year)
Revenue — +64.3% +34.3% +68.4% +57.5% +18.1% −0.5% −37.4% −42.5% −48.3% +41.8%
EBITDA — — — +89.5% +63.7% −65.1% −25.8% −332.3% — — —
Operating income — — — +90.2% +63.8% −69.4% −44.8% — — — —
Net income — — — +91.9% +67.1% −57.6% −38.3% −300.0% — — —
Diluted EPS — — — — — −59.4% −38.5% −325.0% — — —
Margins
Gross margin 12.3% 17.7% 24.1% 25.8% 25.3% 20.7% 20.9% 19.4% 26.2% 38.5% 38.3%
EBITDA margin −4.4% 1.0% 9.1% 10.2% 10.6% 3.1% 2.3% −8.7% −6.5% −23.1% −9.5%
Operating margin −4.5% 0.9% 8.9% 10.0% 10.4% 2.7% 1.5% −10.1% −8.6% −25.9% −11.3%
Net margin −4.2% 1.5% 8.2% 9.3% 9.9% 3.6% 2.2% −7.0% −8.8% −41.5% −15.5%
Free-cash-flow margin −1.1% 0.4% 10.6% 18.9% 6.8% 1.1% −4.5% −19.3% 11.6% −14.1% −10.1%
Cash flow
Cash from operations −1 3 37 103 61 24 −36 −117 43 −24 −26
Capital spending 0 2 3 2 5 13 7 1 2 1 1
Free cash flow −2 1 33 100 57 11 −44 −118 41 −26 −26
Stock-based pay 9 9 10 20 8 10 13 7 9 5 2
Free cash flow after stock pay −10 −8 24 81 49 1 −57 −126 32 −31 −29
Balance sheet
Cash 34 22 56 210 259 348 230 129 134 91 57
Total debt — — 1 3 0 9 130 165 187 137 171
Net debt (negative = net cash) −34 −22 −55 −207 −259 −339 −100 37 53 46 114
Diluted shares 9m 10m 14m 14m 16m 16m 17m 15m 15m 16m 16m
Returned to shareholders
Dividends — — — — 1 — — 6 — — —
Buybacks 3 — — 1 — — 2 8 3 2 1
Total returned 3 — — 1 1 — 2 14 3 2 1

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Older annual columns retain the reporting standard and currency used in those filings, translated separately to USD. Current filings replace overlapping periods. Reporting changes can affect comparability; older bases are not used to fill current valuation inputs.

Financial health

3 of 7 checks passed · December 31, 2025
What it owns · $565m
Short-term assets $294mLonger-term assets $271m
What it owes, and who funded it · $565m
Short-term liabilities $287mLonger-term liabilities $63mShareholders' equity $215m
  • Short-term assets cover short-term liabilities $294m of assets due within a year against $287m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $294m short-term assets against $63m of longer-dated liabilities.
  • More cash than debt $57m of cash against $59m of debt.
  • Debt below 40% of shareholders' equity Debt is 28% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 2% to 28% over five years.
  • A year's operating cash flow covers at least 20% of debt −$26m of operating cash flow against $59m of debt.
  • Operating profit covers interest at least five times over Operating income of −$29m against $6m of interest.

From Zepp Health Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$1.2M
Buybacks, last 3 fiscal years
$6M
Diluted share count
−1.7%
year over year
Total shareholder yield
3.5%
dividends 0.0% + buybacks 3.5% of market value
R&D spending
17.5%
of revenue
Days sales outstanding
94 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in consumer electronics
Last 12 months unless stated ZEPP UEIC GPRO ISPR SONO FXHO Median
Revenue, last 12 months $259m $331m $569m $96m $1.5bn $28m $96m
Revenue growth, last 12 months 41.8% −17.9% −23.9% −24.7% 5.6% −20.5% −17.9%
Revenue growth, 3-year average — −12.1% −18.3% −6.0% −3.7% — −4.8%
Revenue growth, latest quarter — −25.0% −31.3% 32.5% 8.8% — −7.6%
Gross margin 38.3% 29.6% 27.7% 12.8% 46.5% 1.0% 27.7%
Operating margin −11.3% −0.8% −21.2% −33.9% 4.4% −11.1% −12.0%
Operating margin, 3-year average −0.3% −3.2% −15.4% −24.3% −0.7% — −8.4%
Net margin −15.5% −4.6% −27.6% −34.6% 3.8% −14.2% −14.2%
Cash from operations / revenue −9.9% 3.5% −3.5% −0.6% 9.9% −74.5% −3.5%
Free-cash-flow margin −10.1% 2.5% −4.1% −0.9% 8.4% −74.5% −4.1%
Free-cash-flow margin, 3-year average −1.3% 3.8% −7.0% −7.0% 8.4% — −3.3%
Stock pay / revenue 1.0% 0.9% 2.8% 3.6% 4.3% 44.2% 2.5%
Change in share count −1.7% 0.3% 5.0% 0.8% 0.7% >999% 0.3%

Median of all 11 companies we cover in consumer electronics. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

11 consumer electronics companies
Measure Company Peer median Rank
Revenue growth Growth 41.8% -17.9% 2 of 11
Change in growth rate Growth +90.0pp -2.8pp 1 of 11
Gross margin Profitability 38.3% 27.7% 4 of 11
Operating margin Profitability -11.3% -11.3% 5 of 10
Net margin Profitability -15.5% -14.2% 7 of 11
Free-cash-flow margin Cash generation -10.1% -4.1% 7 of 11
Stock pay as % of revenue Cash generation 1.0% 2.8% 3 of 9
Change in share count Balance sheet -1.7% 0.3% 1 of 10
Days sales outstanding Balance sheet 94 days 53 days 10 of 10

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$11.8M
Institutions reporting
26
Shares held vs prior quarter
▼ 34.7%
Positions opened / closed
8 / 11

Top buyers and sellers, Q2 2026: 17 institutions bought and 17 sold ; the biggest buyer was Yiheng Capital Management, L.P (+163K shares) and the biggest seller Point72 Asset Management, L.P (−578K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Morgan Stanley $3.9M 742K 32.9% ▲ 4.8%
Fil Ltd $3.7M 718K 31.8% ▲ 0.1%
Price T Rowe Associates Inc $1.6M 312K 13.8% 0.0%
Yiheng Capital Management, L.P. $1.1M 221K 9.8% ▲ 281.9%
Allspring Global Investments Holdings, LLC $243,557 47K 2.1% 0.0%
Citigroup Inc $208,400 40K 1.8% 0.0%
Mirae Asset Global Etfs Holdings Ltd. $157,910 30K 1.3% ▼ 2.8%
Marshall Wace, LLP $136,258 26K 1.2% New
Susquehanna International Group, LLP $124,352 24K 1.1% New
UBS Group AG $117,590 23K 1.0% ▼ 34.2%
Engineers Gate Manager LP $108,978 21K 0.9% ▲ 44.4%
Axq Capital, LP $85,329 16K 0.7% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Zepp Health Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $87,451 3 trades by 2 insiders · 0% under pre-set plans
Net ▼ $87,451 net selling
Insider Date Trade Shares Price Value
Yu Pengtao Chief Industrial Designer September 24, 2026 Sell 4,251 $4.09 $17,387
Yu Pengtao Chief Industrial Designer September 23, 2026 Sell 5,749 $4.30 $24,721
Deng Cheng Chief Financial Officer June 26, 2026 Sell 9,836 $4.61 $45,344

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Zepp Health Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Zepp Health Corp in brief

What does Zepp Health Corp do?
Zepp Health Corp is a US-listed company in the consumer electronics industry. Its financial year ends in December.
What is Zepp Health Corp's stock ticker?
Zepp Health Corp trades under the ticker ZEPP on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Zepp Health Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Zepp Health Corp reported revenue of $259M, 41.8% higher than a year earlier, according to its SEC filings.
What is Zepp Health Corp's free cash flow?
Zepp Health Corp's free-cash-flow margin is -10.1% of revenue over the trailing twelve months, ranking 7 of the 11 consumer electronics companies we cover.
Who are Zepp Health Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Morgan Stanley, Fil Ltd and Price T Rowe Associates Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Zepp Health Corp buying back stock, and does it pay a dividend?
Zepp Health Corp spent $1.2M on share repurchases over the trailing twelve months, and its diluted share count fell 1.7% over the year.
What is Zepp Health Corp's market cap?
On December 31, 2025, Zepp Health Corp's market capitalisation was about $428M and net debt of $114M. Market figures come from third-party market data and may be delayed.
How much debt does Zepp Health Corp have?
Zepp Health Corp's debt-to-equity ratio is 27.7%, from its latest balance sheet (2.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are Zepp Health Corp's competitors?
In our Consumer Electronics peer group, the companies closest to Zepp Health Corp are Universal Electronics Inc, Gopro, Inc., Ispire Technology Inc., Sonos Inc and Utime Ltd. The side-by-side comparison below sets their revenue, margins and growth against Zepp Health Corp's.
Are insiders buying or selling Zepp Health Corp stock?
Over the last 12 months, Zepp Health Corp's directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is Zepp Health Corp's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Zepp Health Corp announces its own schedule.